BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla ...

Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access ...

The more you learn about and use artificial intelligence (AI), the more you will see your skill set improve. The best is yet to come as you embrace and adapt to the changes.